Revised Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transgene Biotek reported revised audited financial results for FY25 with revenue from operations of Rs 26.07 lakhs (up from Rs 23.49 lakhs last year) and a net loss of Rs 67.61 lakhs versus Rs 65.55 lakhs in FY24. Total expenses rose sharply to Rs 172.03 lakhs (from Rs 107.30 lakhs), driven mainly by legal/commission and finance costs. The auditor M/s Vasavi & Co issued an unmodified (clean) opinion on both standalone and consolidated results. The company disclosed a major contingent liability: an Enforcement Directorate order dated December 30, 2024 imposing a Rs 203.02 crore penalty under FEMA related to an older GDR issue, which the company is challenging before the Appellate Tribunal (next hearing July 27, 2025). Standalone net worth remains deeply negative at Rs -756.75 lakhs.
Persistent losses combined with negative net worth and a Rs 203 crore ED penalty create material going-concern and overhang risks for shareholders, though the oral insulin clinical studies reportedly progressing without side effects is a modest positive for long-term prospects.